394653-40-8

Usage

Uses

Used in Organic Synthesis:
(+/-)-3-oxetanylglycine methyl ester is used as a building block in organic synthesis for the creation of complex molecules, leveraging its unique four-membered ring structure and methyl ester functionality.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (+/-)-3-oxetanylglycine methyl ester is used as a precursor for the synthesis of pharmaceutical compounds, contributing to drug development by providing a foundation for the design of new therapeutic agents.
Used in Drug Development:
(+/-)-3-oxetanylglycine methyl ester is employed in drug development as a precursor molecule, offering potential applications in the creation of novel pharmaceuticals due to its chemical properties and ease of modification.
Used in Chemical Property Manipulation:
The methyl ester functionality in (+/-)-3-oxetanylglycine methyl ester allows for the easy manipulation and modification of its chemical properties, making it a valuable tool in organic chemistry for adjusting reactivity and solubility, among other characteristics.

Upstream product

• 394653-39-5 N-benzyloxycarbonyl-α,β-didehydro-(3-oxetanyl)glycine methyl ester 

Downstream Products

• 1408074-43-0 (R)-2-((tert-butoxycarbonyl)amino)-2-(oxetan-3-yl)acetic acid 
• 1255717-04-4 methyl 2-(benzyloxycarbonylamino)-2-(oxetan-3-yl)acetate 
• 1616889-73-6 C₁₃H₁₅NO₅ 
• 1213783-62-0 (S)-methyl 2-(benzyloxycarbonylamino)-2-(oxetan-3-yl)acetate 
• 1270019-87-8 2-amino-2-(oxetan-3-yl)acetic acid 

Relevant academic research and scientific papers

Improving the metabolic stability of antifungal compounds based on a scaffold hopping strategy: Design, synthesis, and structure-activity relationship studies of dihydrooxazole derivatives

L-amino alcohol derivatives exhibited high antifungal activity, but the metabolic stability of human liver microsomes in vitro was poor, and the half-life of optimal compound 5 was less than 5 min. To improve the metabolic properties of the compounds, the scaffold hopping strategy was adopted and a series of antifungal compounds with a dihydrooxazole scaffold was designed and synthesized. Compounds A33-A38 substituted with 4-phenyl group on dihydrooxazole ring exhibited excellent antifungal activities against C. albicans, C. tropicalis and C. krusei, with MIC values in the range of 0.03–0.25 μg/mL. In addition, the metabolic stability of compounds A33 and A34 in human liver microsomes in vitro was improved significantly, with the half-life greater than 145 min and the half-life of 59.1 min, respectively. Moreover, pharmacokinetic studies in SD rats showed that A33 exhibited favourable pharmacokinetic properties, with a bioavailability of 77.69%, and half-life (intravenous administration) of 9.35 h, indicating that A33 is worthy of further study.

FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF

The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE

Compounds having a structure of Formula (IX) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.

FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF

The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.

The discovery of potent nonstructural protein 5A (NS5A) inhibitors with a unique resistance profile - Part 2

In ongoing studies towards novel hepatitis C virus (HCV) therapeutics, inhibitors of nonstructural protein 5A (NS5A) were evaluated. Specifically, starting from previously reported lead compounds, peripheral substitution patterns of a series of biaryl-linked pyrrolidine NS5A replication complex inhibitors were probed and structure-activity relationships were elucidated. Using molecular modelling and a supercritical fluid chromatographic (SFC) technique, intramolecular H-bonding and peripheral functional group topology were evaluated as key determinants of activity and membrane permeability. The novel compounds exhibited retained potency as compared with the lead compounds, and also showed promising results against a panel of resistance viruses. Together, the results of the study take us a step closer towards understanding the potency of daclatasvir, a clinical candidate upon which the compounds were based, and to designing improved analogues as second-generation antiviral agents targeting NS5A. Refining the resistance: An investigation into the anti-hepatitis C virus (HCV) replicon activity of a series of biaryl-linked prolinamide NS5A inhibitors explored intramolecular H-bonding and peripheral functional group topology as key determinants of activity and membrane permeability. Studies of several peripheral group molecular designs resulted in compounds with improved aqueous solubility and a unique resistance profile.

DIPEPTIDE AND TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS

Provided herein are dipeptide and tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of proliferative diseases including cancer and autoimmune diseases.

HETEROARYL BTK INHIBITORS

The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

Synthesis and preliminary biological evaluation at the glycineB site of (+)- and (-)-3-oxetanylglycine, novel non-proteinogenic amino acids

Two novel non-proteinogenic amino acids, (+)- and (-)-3-oxetanylglycine were synthesized and evaluated for their ability to diplace [3H]-glycine from the glycine site of the NMDA receptor complex. The lack of activity of these compounds at conc